GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Cyclically Adjusted PS Ratio

GILD (Gilead Sciences) Cyclically Adjusted PS Ratio : 4.42 (As of May. 29, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PS Ratio?

As of today (2025-05-29), Gilead Sciences's current share price is $108.44. Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $24.55. Gilead Sciences's Cyclically Adjusted PS Ratio for today is 4.42.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

GILD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.68   Med: 4.59   Max: 21.39
Current: 4.42

During the past years, Gilead Sciences's highest Cyclically Adjusted PS Ratio was 21.39. The lowest was 2.68. And the median was 4.59.

GILD's Cyclically Adjusted PS Ratio is ranked worse than
74.9% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs GILD: 4.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gilead Sciences's adjusted revenue per share data for the three months ended in Mar. 2025 was $5.295. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $24.55 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PS Ratio Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.62 3.86 4.01 3.46 3.79

Gilead Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 2.84 3.44 3.79 4.56

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PS Ratio falls into.


;
;

Gilead Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Gilead Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=108.44/24.55
=4.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Gilead Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=5.295/134.9266*134.9266
=5.295

Current CPI (Mar. 2025) = 134.9266.

Gilead Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 5.353 100.684 7.174
201509 5.519 100.392 7.418
201512 5.786 99.792 7.823
201603 5.520 100.470 7.413
201606 5.739 101.688 7.615
201609 5.601 101.861 7.419
201612 5.525 101.863 7.318
201703 4.928 102.862 6.464
201706 5.422 103.349 7.079
201709 4.937 104.136 6.397
201712 4.510 104.011 5.851
201803 3.855 105.290 4.940
201806 4.318 106.317 5.480
201809 4.282 106.507 5.425
201812 4.482 105.998 5.705
201903 4.116 107.251 5.178
201906 4.452 108.070 5.558
201909 4.423 108.329 5.509
201912 4.615 108.420 5.743
202003 4.369 108.902 5.413
202006 4.098 108.767 5.084
202009 5.216 109.815 6.409
202012 5.793 109.897 7.112
202103 5.090 111.754 6.145
202106 4.934 114.631 5.808
202109 5.880 115.734 6.855
202112 5.740 117.630 6.584
202203 5.222 121.301 5.809
202206 4.968 125.017 5.362
202209 5.584 125.227 6.017
202212 5.841 125.222 6.294
202303 5.037 127.348 5.337
202306 5.246 128.729 5.499
202309 5.609 129.860 5.828
202312 5.669 129.419 5.910
202403 5.362 131.776 5.490
202406 5.558 132.554 5.657
202409 6.017 133.029 6.103
202412 5.918 133.157 5.997
202503 5.295 134.927 5.295

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (NAS:GILD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Gilead Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711